Research Papers:

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations

Zhigang Wei, Xin Ye _, Xia Yang, Aimin Zheng, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Min Meng and Yang Ni

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:56714-56725. https://doi.org/10.18632/oncotarget.18083

Metrics: PDF 1410 views  |   HTML 1909 views  |   ?  


Zhigang Wei1, Xin Ye1, Xia Yang1, Aimin Zheng1, Guanghui Huang1, Wenhong Li1, Jiao Wang1, Xiaoying Han1, Min Meng1 and Yang Ni1

1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China

Correspondence to:

Xin Ye, email: [email protected]

Keywords: epidermal growth factor receptor, tyrosine kinase inhibitors, non-small cell lung cancer, microwave ablation, progression free survival

Received: March 27, 2017    Accepted: April 27, 2017    Published: May 23, 2017


We conducted this retrospective study to investigate whether microwave ablation (MWA) of primary tumor sites plus epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) could improve survival in advanced non small cell lung cancer (NSCLC) with EGFR mutations. MWA was conducted at the primary tumor sites, followed by EGFR-TKIs in the MWA plus EGFR-TKIs group. EGFR-TKIs were administered until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and objective response rate (ORR). A total of 58 patients were recruited, including 34 in the MWA plus EGFR-TKIs group and 24 in the EGFR-TKIs group. No significant difference in ORR was observed with MWA treatment (61.8% vs. 45.8%, p = 0.230). Patients treated with MWA plus EGFR-TKIs failed to show superior survival in either PFS (13.2 months vs. 11.6 months, p = 0.640) or OS (39.8 months vs. 20.4 months, p = 0.288). MWA was not an independent prognostic factor for PFS or OS. MWA of primary tumor sites plus EGFR-TKIs demonstrated no survival advantage compared with EGFR-TKIs alone in advanced NSCLC patients with EGFR sensitive mutations. MWA should not be recommended for unselected patients with EGFR-sensitive mutations.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18083